Role of plasminogen activator inhibitor type 1 (PAI-1) in PCOS patient

In a 2017 study by Sahay et al., researchers found that patients with Polycystic Ovarian Syndrome (PCOS) had significantly higher levels of plasminogen activator inhibitor type 1 (PAI-1) compared to healthy controls. The study included 50 PCOS patients and 25 controls, and it demonstrated that elevated PAI-1 levels were significantly correlated with factors such as body mass index (BMI), waist-to-hip ratio, fasting glucose and insulin levels, triglycerides, low-density lipoprotein (LDL), and insulin resistance measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). The study suggested that high PAI-1 levels could be associated with increased risks of atherosclerosis, cardiovascular diseases, menstrual disturbances, and infertility in PCOS patients. However, the study had limitations such as a small sample size and did not analyze other components of fibrinolytic activities.